Immunocore (NASDAQ:IMCR) Posts Earnings Results

Immunocore (NASDAQ:IMCRGet Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.12), reports. Immunocore had a negative net margin of 22.60% and a negative return on equity of 16.54%. The firm had revenue of $70.30 million for the quarter, compared to analysts’ expectations of $70.72 million. During the same quarter in the previous year, the firm posted ($0.35) EPS. The firm’s revenue for the quarter was up 27.6% compared to the same quarter last year.

Immunocore Trading Down 1.5 %

Shares of IMCR opened at $58.95 on Friday. Immunocore has a 52-week low of $42.21 and a 52-week high of $76.98. The stock has a market cap of $2.94 billion, a PE ratio of -48.32 and a beta of 0.92. The firm’s fifty day moving average is $60.44 and its two-hundred day moving average is $61.41. The company has a quick ratio of 3.77, a current ratio of 5.96 and a debt-to-equity ratio of 1.22.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on IMCR. Leerink Partnrs reiterated an “outperform” rating on shares of Immunocore in a research note on Monday, April 29th. HC Wainwright lifted their target price on shares of Immunocore from $90.00 to $100.00 and gave the company a “buy” rating in a report on Thursday. Mizuho lifted their price objective on shares of Immunocore from $86.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, March 5th. Oppenheimer reiterated an “outperform” rating and issued a $87.00 price objective (up previously from $85.00) on shares of Immunocore in a research report on Thursday, February 29th. Finally, Canaccord Genuity Group raised their target price on Immunocore from $63.00 to $67.00 and gave the company a “hold” rating in a research report on Thursday. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, Immunocore currently has an average rating of “Moderate Buy” and a consensus price target of $82.00.

Read Our Latest Stock Report on IMCR

About Immunocore

(Get Free Report)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.

Featured Articles

Earnings History for Immunocore (NASDAQ:IMCR)

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with's FREE daily email newsletter.